Dr. Thierry Wurch, Director of External Studies in Immuno-oncology, Servier, summarizes his talk about the use of UCART19 against CD19-expressing hematological malignancies and the impressive clinical benefits leading to the marketing of the two first autologous CART-cell products Kymriah (Novartis) and
Yescarta (Kite Gilead).
Watch the entire lecture: https://bit.ly/2IHG2sb
More information about the Sartorius Research Xchange Forum on Trends and Challenges in Regenerative Medicine and Cell Therapy 2018: https://promotions.sartorius.com/rxf2018/#
